Mandragora
Viewing r2 — May 14, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Mandrake (Mandragora officinarum L., Solanaceae) is a perennial Mediterranean plant whose roots, leaves, and berries produce tropane alkaloids that classify it as a deliriant. Its principal psychoactive constituent, hyoscyamine, is a competitive muscarinic acetylcholine receptor antagonist. Hyoscyamine produces its effects by blocking central muscarinic signaling, disrupting cholinergic neurotransmission across cortical and subcortical circuits.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
atropine, scopolamine, Datura stramonium +2 moreatropine, scopolamine, Datura stramonium, Atropa belladonna, Hyoscyamus niger show less
Mandrake appears as "dudaim" in the Hebrew Bible and was described by Dioscorides in the 1st century AD as a surgical anesthetic.[1][2] It featured in medieval European anesthetic formularies before synthetic anticholinergics displaced it from clinical use.[3] No clinical trials have been registered for any Mandragora species, and contemporary recreational use is extremely rare.[4]
Subjective effects include disoriented delirium, vivid but fragmented hallucinations, complete amnesia, and inability to distinguish hallucinated content from reality.[5] The experience is qualitatively distinct from serotonergic psychedelics — hallucinations are mundane in content, seamlessly integrated into perceived reality, and accompanied by global cognitive disorganization. Characteristic unsought effects include tachycardia, pupil dilation, hyperthermia, dry mouth, and profound dysphoria.[4]
No physical dependence syndrome has been documented for anticholinergic agents, and compulsive use is unlikely given the characteristically dysphoric experience.[4] Mandragora preparations carry an extremely narrow margin between perceptible effect and severe anticholinergic toxicity, with the dominant real-world harm pathway being accidental consumption of berries mistaken for edible plants.[6] No controlled human pharmacokinetic data, quantified dose-response relationships, or standardized preparations exist for any Mandragora species.
History[edit]
Traditional and historical use
Mandragora is among the earliest documented medicinal plants in the Western and Near Eastern pharmacopoeia, appearing as "dudaim" in the Hebrew Bible (Genesis 30:14–16) in association with fertility.[1] A spatiotemporal analysis of 292 vernacular names across 41 languages identified the Near East as the origin of the plant's mythology, with the most common name categories relating to anthropomorphism, supernatural agents, narcotic effects, and aphrodisiac properties.[7]
Dioscorides provided the first explicit description of mandrake-induced anesthesia in the 1st century AD, recording approximately 1 cyathus (~45 mL) of root decoction boiled in wine and administered orally before surgical procedures. Traditional preparation forms included fresh root juice, root boiled in wine, root bark infusion, and sun-dried fruit. These remain traditional-use accounts without clinical confirmation.
Medieval European use
Mandrake featured in the "spongia somnifera" — a medieval surgical tool incorporating narcotic plant materials (mandrake, henbane, opium) as an inhalation preparation for anesthesia. The 13th-century physician Teodorico Borgognoni is recognized as a forerunner of modern anesthesia for his use of such formularies.[2]
The plant was also a component of unguentum sabbati ("witches' ointment") recipes, typically combined with belladonna and henbane in animal fat and applied transdermally. The anticholinergic alkaloids — particularly scopolamine — are pharmacologically capable of transdermal absorption, producing intense delirium and sensory distortions historically interpreted as "flying".citation needed
Modern era
Linnaeus formalized the binomial Mandragora officinarum in Species Plantarum (1753),[8] with the authoritative taxonomic revision produced by Ungricht, Knapp, and Press in 1998.[9] Traditional medicinal uses documented across the Mediterranean, North Africa, and Himalayan regions include treatment of insomnia, pain, hemorrhoids, and melancholia.[10][11]
Pharmaceutical interest in Mandragora specifically declined as synthetic anticholinergics became available. Both atropine and scopolamine — derived from related Solanaceae — now appear on the WHO List of Essential Medicines.[3] A survey of hallucinogen users in Slovenia found that knowledge of anticholinergic Solanaceae has been largely lost, attributed to severe toxicity and characteristically unpleasant effects.[4]
Botanical Overview[edit]
Mandragora is a genus of perennial herbaceous plants in the family Solanaceae (nightshades), closely related to Atropa belladonna, Hyoscyamus niger, and Datura stramonium. Three pharmacologically significant species are recognized: M. officinarum L. (spring mandrake), M. autumnalis Bertol. (autumn mandrake), and M. turcomanica. Each carries a distinct alkaloid profile with direct consequences for psychoactive character — M. officinarum produces hyoscyamine but lacks scopolamine entirely, while M. autumnalis contains both alkaloids.[12]
The genus is native to the Mediterranean basin, with populations documented across southern Europe, North Africa, the Levant, and extending into Himalayan regions. M. officinarum and M. autumnalis co-occur in parts of the Mediterranean but differ in flowering season — spring and autumn respectively. The plants grow in rocky, calcareous soils and disturbed ground at low to moderate elevations. Mandragora is not widely cultivated commercially and is primarily encountered as wild populations or specialty horticultural specimens.
The plant produces a large, fleshy, branching taproot — often forked in a shape historically interpreted as anthropomorphic, which generated extensive mythology. Above ground, it forms a basal rosette of large, wrinkled, dark green leaves. Flowers are bell-shaped, typically purple or greenish-white depending on species. The fruit is an orange-yellow berry when ripe, approximately 2–3 cm in diameter.
The berries and leaves are the most common source of accidental poisoning, as they can be mistaken for edible plants such as borage or spinach.[6] All parts of the plant contain tropane alkaloids, with concentrations varying by species, plant part, developmental stage, and growing conditions.
Alkaloid Profile[edit]
The dominant alkaloids in Mandragora are tropane alkaloids — principally hyoscyamine and, in certain species, scopolamine. These are competitive antagonists at muscarinic acetylcholine receptors (M₁–M₅), producing both peripheral and central anticholinergic effects.[5][3] Hyoscyamine racemizes to atropine during extraction and drying, so both forms are typically present in preparations made from dried plant material.
The species consumed determines the alkaloid composition. M. officinarum produces high levels of hyoscyamine but lacks scopolamine entirely, while M. autumnalis contains both alkaloids due to a functional hyoscyamine 6β-hydroxylase enzyme that converts hyoscyamine to scopolamine.[12] This enzymatic difference means the two species produce pharmacologically distinct profiles — M. autumnalis preparations carry greater CNS-penetrant alkaloid load because scopolamine crosses the blood-brain barrier more readily than hyoscyamine or atropine.
Scopolamine produces more pronounced sedation, amnesia, and hallucinations at lower doses relative to peripheral effects. Hyoscyamine and atropine produce prominent peripheral anticholinergic effects: pupil dilation, dry mouth, tachycardia, urinary retention, decreased bowel motility, and bronchodilation.
Beyond the principal tropane alkaloids, Mandragora contains non-alkaloid constituents including withanolides and coumarins. Whether these compounds modulate the pharmacological activity of the tropane alkaloids in whole-plant preparations remains unknown — no studies have examined the interaction between tropane alkaloids and the plant's non-alkaloid matrix.
Alkaloid concentrations vary substantially by species, plant part, developmental stage, and growing conditions. No analytical data characterizing batch-to-batch variability in wild-harvested material have been published, and no standardized commercial preparations exist. This variability makes dose prediction from raw plant material impossible.
Neuroscience[edit]
Where it acts
The tropane alkaloids in Mandragora block muscarinic acetylcholine receptors (M₁–M₅) throughout the central and peripheral nervous system.[5][3] No serotonergic or glutamatergic receptor involvement has been documented — the hallucinatory profile is exclusively anticholinergic. Scopolamine crosses the blood-brain barrier more readily than hyoscyamine, which is why M. autumnalis (containing both alkaloids) likely produces more pronounced central effects relative to peripheral symptoms.
What it changes
At supratherapeutic doses, central muscarinic blockade produces a deliriant syndrome — disoriented delirium with vivid hallucinations, abolished reality testing, and dense amnesia.[5] This differs fundamentally from serotonergic psychedelia: there are no geometric visuals, no emotional deepening, and no preserved insight. The hallucinations are mundane — conversations with absent people, interactions with nonexistent objects — and seamlessly woven into perceived reality. Tolerance to anticholinergic effects develops with repeated pharmaceutical scopolamine and atropine administration, though the mechanism in whole-plant preparations is uncharacterized.
Key unknowns include: (1) whether the alkaloid ratio differences between M. officinarum and M. autumnalis produce qualitatively distinct intoxication profiles; (2) the pharmacokinetics of transdermal absorption from historical ointment preparations; and (3) the interaction between tropane alkaloids and the plant's non-alkaloid constituents (withanolides, coumarins) in whole-plant preparations.
Subjective Effects[edit]
The defining character of Mandragora intoxication is the abolition of reality testing. Hallucinated content — typically mundane, such as conversations with absent persons or interactions with nonexistent objects — is seamlessly integrated into perceived reality with no awareness that the experience is drug-induced. This is accompanied by agitated confusion, dense amnesia, and prominent peripheral effects including dry mouth, tachycardia, pupil dilation, and hyperthermia. The species consumed determines the alkaloid mix and likely modulates the ratio of central to peripheral effects, though this has not been empirically compared.
Mandragora intoxication belongs to the same pharmacological class as Datura stramonium and Atropa belladonna — anticholinergic Solanaceae whose effects arise from muscarinic acetylcholine receptor blockade rather than monoamine or indoleamine modulation. The experience is qualitatively distinct from classical psychedelics, dissociatives, and cannabis: there is no geometric visual patterning, no emotional deepening or mystical phenomenology, and no preserved insight during the episode.
Effect Grid
No common dose has been established for any Mandragora preparation. At moderate anticholinergic exposure — inferred from class pharmacology — confusion and cognitive impairment become prominent. Spatial disorientation, temporal disorientation, and focus suppression emerge. Early hallucinations may begin, particularly in scopolamine-containing M. autumnalis preparations, with reality testing beginning to degrade.
Physical effects are marked: pronounced dry mouth, significant tachycardia, full mydriasis with light sensitivity, flushed skin, and temperature dysregulation from anhidrosis. Nausea, dizziness, and motor control impairment are typical. Urinary retention may occur.
This tier represents the boundary between peripheral-dominant and central-dominant anticholinergic effects. The margin between this level and severe toxicity is extremely narrow and unpredictable.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Peripheral misidentification · Vestibular distortion · Visual haze / noise · Auditory misinterpretation · Auditory distortion · Proprioceptive distortion · External hallucinations · Auditory hallucinations · Internal hallucinations · Visual processing suppression · Shadow people
Auditory distortion · Proprioceptive distortion · External hallucinations · Auditory hallucinations · Internal hallucinations · Visual processing suppression · Shadow people
Sedation · Dehydration sensation · Heart rate perception changes · Physical fatigue · Restlessness · Temperature dysregulation · Constipation · Headache · Muscle relaxation · Nausea · Nystagmus (eye wobbles) · Trembling · Vomiting · Bodily dissociation · Tactile hallucination
Physical fatigue · Restlessness · Constipation · Headache · Muscle relaxation · Nausea · Nystagmus (eye wobbles) · Trembling · Vomiting · Bodily dissociation · Tactile hallucination
Information processing suppression · Thought disorganization · Analysis suppression · Memory suppression · Cognitive dysphoria · Cognitive fatigue · Memory fragmentation · Suggestibility enhancement · Language suppression · Motivation suppression · Thought deceleration · Thought loops · Delirium · Amnesia · Delusions
Memory suppression · Cognitive dysphoria · Cognitive fatigue · Memory fragmentation · Language suppression · Motivation suppression · Thought deceleration · Thought loops · Delirium · Amnesia · Delusions
Anxiety suppression · Euphoria
Disinhibition · Emotional susceptibility · Automaticity · Depersonalization · Derealization · Cognitive disconnection · Identity alteration
Derealization · Cognitive disconnection · Identity alteration
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- No data
- Withdrawal
- None
- Tolerance buildup
- slow
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- atropine · scopolamine · Datura stramonium
Toxicity
No LD50 has been established for whole-plant Mandragora preparations in any species. No controlled toxicity data exist. The safety profile derives entirely from clinical case reports and extrapolation from pharmaceutical anticholinergic literature.
Acute poisoning produces the classic anticholinergic toxidrome: hyperthermia from anhidrosis, dry mucous membranes, cutaneous flushing, pupil dilation with visual acuity suppression, and excited delirium with hallucinations and amnesia.[5]
Two adults in Crete developed supraventricular tachycardia (pulse 170–190 bpm), nausea, vomiting, blurred vision, and flushed skin after eating Mandragora berries mistaken for borage. Tachycardia persisted for 5 days; treatment required physostigmine 1 mg IV daily following gastric lavage. Both recovered fully within 10 days.[6] A separate case confirmed poisoning from berries consumed as a believed aphrodisiac via analytical toxicology.[13]
A fatal scopolamine case — an inmate who smoked scopolamine tablets — demonstrated lethality at peripheral blood concentrations of 14 ng/mL, with cerebral and pulmonary edema on pathology.[14] While not a Mandragora preparation, this establishes that scopolamine at toxic concentrations is directly lethal.
Mandragora is wild-harvested with no standardized commercial preparations, no FDA or EMA-approved products, and no quality control infrastructure. Key contamination and safety vectors include:
- Misidentification as food plants: documented cause of clinical poisoning — berries and leaves mistaken for borage, spinach, or other leafy vegetables[6]
- Commercial mislabeling: North American products sold as "mandrake" may contain Podophyllum peltatum (a cytotoxic lignan source) instead of Mandragora officinarum — two plants with radically different toxicological profiles[15]
- Batch variability: alkaloid concentrations vary by species, plant part, developmental stage, and growing conditions — no standardization is possible from wild material
- Absence of testing: no ISO/IEC-accredited laboratory testing programs, Certificate of Analysis requirements, or regulated supply chain exist for Mandragora preparationscitation needed
Psychological Risks
The deliriant syndrome is characterized by global cognitive disorganization, agitated confusion, vivid hallucinations indistinguishable from reality, and complete or partial amnesia.[5] Unlike serotonergic psychedelics, reality testing is abolished — the user cannot recognize the hallucinatory nature of the experience during the episode.
Severe psychological distress during anticholinergic delirium is the norm rather than the exception. The experience is consistently described as frightening, confusing, and dysphoric.[4] No dose titration strategy has been established that reliably produces psychoactive effects without risk of severe toxicity.
Persistent psychological sequelae from acute anticholinergic intoxication have not been systematically studied. Chronic anticholinergic exposure is associated with cognitive decline and increased dementia risk in pharmacoepidemiological studies, though this literature applies to sustained therapeutic dosing rather than acute plant intoxication.citation needed
Tolerance & Dependence
No published data on tolerance, physical dependence, or withdrawal exist for Mandragora preparations specifically. Tolerance to anticholinergic effects is recognized with repeated pharmaceutical scopolamine and atropine administration, but no physical dependence syndrome or characterized withdrawal has been documented for anticholinergic agents as a class.
Compulsive use of Mandragora or related anticholinergic Solanaceae is unlikely. A survey of hallucinogen users found that knowledge of these plants has been largely lost, attributed to severe toxicity and characteristically unpleasant effects.[4]
Drug Interactions
Herb-drug interaction data specific to Mandragora preparations do not exist. The following interactions are derived from pharmacological principles and pharmaceutical studies of the isolated alkaloids.
CYP3A4 inhibitors: grapefruit juice increases scopolamine exposure (AUC) to approximately 142% of control and prolongs time to peak concentration, via inhibition of intestinal CYP3A metabolism.[16] Other CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) would produce analogous effects on scopolamine-containing preparations.
Additive anticholinergic burden: Co-administration with other anticholinergic agents — first-generation antihistamines (diphenhydramine), tricyclic antidepressants (amitriptyline), antipsychotics (olanzapine), and urological agents (oxybutynin) — carries risk of synergistic anticholinergic toxicity.
CNS depressants: Additive CNS depression with alcohol, opioids, and benzodiazepines. CNS depressant co-ingestion was noted in a fatal scopolamine case.[14]
Cholinesterase inhibitors: Direct pharmacodynamic antagonism with donepezil, rivastigmine, and galantamine — reduces efficacy of both agents. Clinically significant in dementia patients, where inadvertent anticholinergic exposure from herbal products can undermine therapeutic benefit.
MAO inhibitors: A potential interaction based on shared CNS pathways has been proposed. No specific clinical data exist for Mandragora preparations with MAOIs.citation needed
Contraindications
Cardiac disease: Supraventricular tachycardia exceeding 170 bpm has been documented in Mandragora poisoning.[6] Pre-existing cardiac arrhythmia, coronary artery disease, or heart failure constitutes an absolute contraindication.
Elderly individuals: Enhanced anticholinergic sensitivity in older adults is well established. Severe scopolamine toxicity via transdermal patch was documented in a 66-year-old patient.[17]
Pregnancy: Scopolamine crosses the placenta.[16] Uncontrolled alkaloid exposure from plant preparations and risk of maternal anticholinergic toxidrome constitute a contraindication.
Concurrent anticholinergic medications: Patients taking any medication with anticholinergic properties face additive toxicity risk.
Concurrent cholinesterase inhibitor therapy: Direct pharmacodynamic antagonism creates dual harm — reduced therapeutic efficacy and risk of anticholinergic breakthrough.
Hepatic impairment: Scopolamine undergoes extensive CYP3A4 metabolism.[16] Impaired hepatic function increases systemic exposure and prolongs effect duration.
Pediatric populations: Children are particularly vulnerable to anticholinergic toxidrome.safety citation needed
Glaucoma: Anticholinergic mydriasis can precipitate acute angle-closure glaucoma.citation needed
Urinary obstruction: Anticholinergic urinary retention can exacerbate prostatic hypertrophy or obstructive uropathy.citation needed
Preparations[edit]
No published dose-characterization data exist for any Mandragora preparation, and no standardized commercial supply chain has been established. All preparations carry an extremely narrow and unpredictable margin between perceptible effect and severe anticholinergic toxicity. The following documents historically recorded and real-world exposure forms rather than recommended preparations.
Root decoction in wine
The oldest documented preparation form. Dioscorides recorded approximately 1 cyathus (~45 mL) of root decoction boiled in wine and reduced to one-third volume, administered orally before surgical procedures. Alkaloid concentration in this preparation depends entirely on the root material, species, and boiling duration. This is a traditional-use account without clinical confirmation — no safe dose has been established, and no modern pharmacokinetic data exist for this preparation.
Topical ointment
Historical "witches' ointment" (unguentum sabbati) preparations combined mandrake with belladonna and henbane, rendered in animal fat and applied transdermally. Scopolamine is pharmacologically capable of transdermal absorption — pharmaceutical scopolamine patches achieve steady-state plasma concentrations of 56–245 pg/mL over 72 hours.[16][18] No pharmacokinetic data exist for transdermal absorption from traditional ointment preparations specifically, and alkaloid delivery from crude plant-fat mixtures cannot be compared to pharmaceutical patch formulations.
Raw plant material (accidental ingestion)
The dominant real-world exposure pathway is accidental consumption of berries or leaves mistaken for edible plants such as borage.[6] Documented clinical cases involved eating berries believed to be food or aphrodisiac.[13] The quantity of plant material that produces clinical toxicity is unknown and varies by species, plant part, and individual alkaloid content. No threshold, common, or strong dose ranges can be stated for any raw plant material form.
Oral pharmacokinetics (isolated alkaloids)
No pharmacokinetic data exist for whole-plant Mandragora preparations in humans. For pharmaceutical scopolamine administered orally: tmax approximately 0.5 hours; oral bioavailability 3–27% due to high first-pass hepatic metabolism via CYP3A4; only 2.6% excreted unchanged in urine.[16] Both scopolamine and hyoscyamine cross the blood-brain barrier and placenta readily.[16]
Per-preparation dose tiers, timelines, and bioavailability data are absent from the published literature for all Mandragora preparations. No standardized commercial supply chain exists.
Harm Reduction[edit]
Forms & Identification
Mandragora has no standardized commercial preparations and no regulated supply chain. Products sold as "mandrake" in North America may contain Podophyllum peltatum — an entirely different plant with cytotoxic rather than anticholinergic properties.[15] No Certificate of Analysis programs, ISO-accredited laboratory testing, or quality standards exist for Mandragora products.
Botanical identification is critical: the plant's berries and leaves closely resemble edible species such as borage and spinach, and misidentification is the most documented poisoning pathway.[6] Anyone handling wild Mandragora should confirm identification with a qualified botanist. No reagent test or field kit exists for detecting tropane alkaloid content in raw plant material.
Guidelines
- No safe recreational dose has been established for any Mandragora preparation. The margin between perceptible effect and severe anticholinergic toxicity is extremely narrow and unpredictable due to uncharacterized alkaloid variability.
- Never consume wild plant material without expert botanical identification. Mandragora berries are a documented cause of accidental poisoning when mistaken for edible plants.
- Never combine with other anticholinergic agents — including over-the-counter antihistamines (diphenhydramine, dimenhydrinate), sleep aids, and tricyclic antidepressants. Additive toxicity is the expected outcome.
- Never combine with CNS depressants (alcohol, opioids, benzodiazepines). CNS depressant co-ingestion was noted in a fatal scopolamine case.
- Avoid CYP3A4 inhibitors — including grapefruit juice — which increase scopolamine exposure by approximately 42%.[16]
- Inform a sober companion of what was taken, the expected duration, and when to call emergency services.
- Physostigmine awareness: physostigmine is the specific antidote for anticholinergic toxidrome. Emergency physicians may not immediately consider it without being told the substance involved.
Set & Setting
Anticholinergic delirium abolishes insight and reality testing — the user cannot recognize the experience as drug-induced and cannot make safety decisions during the episode.[5] This fundamentally distinguishes Mandragora from substances where set and setting modulate experience quality. Environmental preparation cannot mitigate the core risk because the user loses all capacity for self-regulation during intoxication.
If exposure occurs, a sober, informed companion who can prevent self-harm and contact emergency services is essential. The setting must be physically safe — no access to roads, bodies of water, heights, or sharp objects. The companion should be briefed on anticholinergic toxidrome recognition and emergency response.
Aftercare & integration. Anticholinergic delirium typically produces dense amnesia — the person may have little or no memory of the experience. Residual confusion, visual disturbance from persistent pupil dilation, and fatigue may continue for 24–48 hours after acute symptoms resolve.
Rehydrate gradually. Anticholinergic effects suppress salivation and normal fluid regulation — oral rehydration with electrolytes is appropriate once the person can swallow safely.
Monitor heart rhythm. In documented cases, supraventricular tachycardia persisted for up to 5 days after Mandragora ingestion.[6] Seek medical follow-up if heart rate remains elevated or irregular.
Liver enzyme monitoring may be warranted — documented cases showed liver enzyme elevation that normalized within 10 days.[6]
The dysphoric and frightening character of anticholinergic delirium may produce acute anxiety or distress in the days following exposure. Professional psychological support is appropriate if distress persists.
Recovery & Support
Compulsive use of Mandragora is extremely rare given the characteristically unpleasant experience.[4] Most exposures are accidental rather than intentional.
For anyone experiencing distress following anticholinergic exposure:
- Poison Control (US): 1-800-222-1222
- SAMHSA National Helpline (US): 1-800-662-4357 (free, confidential, 24/7)
- NHS 111 (UK): for non-emergency medical advice following plant exposure
- European emergency number: 112
If anticholinergic plant exposure was intentional and reflects a pattern of self-harm or substance use disorder, professional evaluation is warranted. Anticholinergic agents do not produce physical dependence, but intentional use of deliriant substances may indicate underlying psychological needs that benefit from clinical support.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Red flags requiring immediate emergency response:
- Heart rate above 150 bpm or irregular heartbeat
- Body temperature rising with hot, dry skin and inability to sweat
- Severe agitation, confusion, or unresponsiveness
- Seizures
- Difficulty breathing
Immediate steps:
- Call emergency services (911 / 112 / local equivalent) immediately.
- Do not leave the person alone — they cannot distinguish reality from hallucination and may harm themselves.
- Move the person to a cool environment. Apply cool water to skin if body temperature is elevated.
- Do not induce vomiting unless instructed by poison control.
- Do not physically restrain unless the person is in immediate danger of self-harm.
What to tell the dispatcher:
- The person consumed Mandragora (mandrake) — a plant containing anticholinergic tropane alkaloids (hyoscyamine, scopolamine).
- Approximate amount and time of ingestion if known.
- Current symptoms: heart rate, temperature, pupil size, mental state.
- Physostigmine is the specific antidote — mention this to ensure the emergency team considers it.
Good Samaritan laws exist in many jurisdictions and provide legal protection for those seeking emergency help.
Legal Status[edit]
Mandragora species are not scheduled under any of the three major UN drug control conventions (1961, 1971, 1988). The principal alkaloids hyoscyamine and scopolamine are also unscheduled internationally, though both are controlled as prescription-only pharmaceutical agents in most jurisdictions when manufactured as medicines. Atropine and scopolamine appear on the WHO List of Essential Medicines.[3] Regulatory treatment varies by jurisdiction, with most countries imposing no specific restrictions on the plant itself.
| Jurisdiction | Status | Notes |
|---|---|---|
| United States (federal) | Uncontrolled | Mandragora officinarum and its extracts are not scheduled under the Controlled Substances Act. Legal to possess, cultivate, buy, and distribute. Supplement sales must conform to DSHEA.[19] |
| Louisiana (US state) | Prohibited for human consumption | Louisiana Act No. 159 (effective August 8, 2005) names Mandragora officinarum among 40 plants prohibited when intended for human consumption. Aesthetic, landscaping, and decorative purposes are exempt.[19] |
| Other US states | No specific bans identified | No state-level prohibitions on Mandragora were identified in published literature.citation needed |
| United Kingdom | Prescription only (M. autumnalis in medicines) | The Prescription Only Medicines (Human Use) Order 1997 identifies M. autumnalis as making medicinal products prescription-only. Whether this extends to M. officinarum is unclear.[19] |
| European Union | No EU-wide scheduling | The European Medicines Agency does not recognize any Mandragora species as an approved herbal medicinal product.[19] |
| Germany | No specific data found | No regulatory data specific to Mandragora were identified.citation needed |
| Australia | No specific data found | No regulatory data specific to Mandragora were identified.citation needed |
| Israel | No specific data found | No regulatory data specific to Mandragora were identified.citation needed |
Detection
Standard immunoassay drug panels do not detect hyoscyamine or scopolamine. Forensic or clinical confirmation requires specific LC-MS/MS methodology.[20][21] Anticholinergic syndrome is typically diagnosed clinically by symptom pattern rather than toxicological screening.
references
- [1] ^abDafni A, Böck B (2019) Medicinal plants of the Bible—revisited — Journal of Ethnobiology and Ethnomedicine doi:10.1186/s13002-019-0338-8
- [2] ^abCavalloro V, Soddu F, Baroni S, et al. (2023) Teodorico Borgognoni's Formulary for Thirteenth Century Anesthetic Preparations — Life (Basel) doi:10.3390/life13091913
- [3]
- [4]
- [5] ^abcdefgLakstygal AM, Kolesnikova TO, Khatsko SL, Zabegalov KN, Volgin AD, Demin KA, Shevyrin VA, Wappler-Guzzetta EA, Kalueff AV (2019) DARK Classics in Chemical Neuroscience: Atropine, Scopolamine, and Other Anticholinergic Deliriant Hallucinogens — ACS Chemical Neuroscience doi:10.1021/acschemneuro.8b00615
- [6]